OmniAb, Inc. (OABI) Stock

OmniAb, Inc., a pioneering biotechnology firm based in Emeryville, California, specializes in cutting-edge therapeutic antibody discovery technologies within the United States. The company's robust discovery platform offers industry partners access to a vast array of antibody repertoires and state-of-the-art screening technologies, facilitating the rapid identification of next-generation therapeutic solutions.

At the heart of OmniAb's capabilities lies its proprietary OmniAb platform, leveraging biological intelligence from genetically modified transgenic animals such as OmniRat, OmniChicken, and OmniMouse. These animals are uniquely engineered to produce antibodies with human sequences, thereby streamlining the development of human therapeutic candidates with enhanced efficacy and reduced immunogenicity.

OmniAb further enhances its offerings with specialized platforms like OmniFlic (transgenic rat) and OmniClic (transgenic chicken), which cater specifically to the growing demand for bispecific antibody applications using a common light chain approach. Additionally, OmniTaur introduces novel structural attributes derived from cow antibodies, addressing the complexities associated with challenging therapeutic targets.

Established in 2012, OmniAb continues to push the boundaries of antibody discovery and development, partnering closely with pharmaceutical and biotechnology companies to advance novel therapies across various disease areas. With a steadfast commitment to innovation and scientific excellence, OmniAb remains at the forefront of transforming biotechnology research into impactful medical breakthroughs.